Farnaz Sohrabvand Corresponding Author
- Department of Gynecology and Obstetrics ,Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Malek Mansour Aghsa
- Department of Gynecology and Obstetrics ,Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Fedyeh Haghollahi
- Vali-e- Asar Reproductive Health Research Center,Tehran Medical Sciences University, Tehran, Iran
Maryam Bagheri
- Vali-e- Asar Reproductive Health Research Center,Tehran Medical Sciences University, Tehran, Iran
Mamak Shariat
- Vali-e- Asar Reproductive Health Research Center,Tehran Medical Sciences University, Tehran, Iran
Ashraf Alyasin
- Department of Gynecology and Obstetrics ,Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Farid Zayeri
- Biostatistics Department, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran

Received: 4/1/2007 Accepted: 4/1/2007 - Publisher : Avicenna Research Institute

Related Articles


Other Format



Introduction: Polycystic Ovary Syndrome (PCOS), which affects 2-20% of women of repro-ductive age, is associated with insulin resistance, hyperandrogenic anovulation and consequently infertility. In addition, in case of getting pregnant, there is a higher risk of spontaneous abortion. This study was done to evaluate the effects of continuing metformin throughout the first trimester of pregnancy. Materials & Methods: Seventy six PCOS patients who became pregnant while on ovulation induction medications and metformin were allocated to three groups in three different clinics during 2004-2005, as it follows: Group A, continuing metformin until the end of the 8th week, group B, until the end of the 12th week and group C, cessation of taking metformin immediately after confirmation of pregnancy (5-6th week of pregnancy). Pregnancy outcomes and complica-tions were followed until the end of pregnancies. The data were analyzed by using SPSS (Version 9) and χ2, t-test, ANOVA, Kruskal Wallis, McNemars test and logistic regression calculations. A p-value<0.05 was considered as the level of significance. results: the mean age of women in the two groups was 28.72±3.57 years, duration of infertility 3.38±2.19 years, bmi 25.7±5.28 and history of abortions 0.40±0.65. in comparison to the rates in previous pregnancies, significant reduction in spontaneous abortion rates were seen in group b from 40% to 8% using mcnemars test (p<0.01) and in group a from 32% to 4% (p="0.002)." in group c, despite a lowered rate of spontaneous abortion (from 23.1% to 4.2%), the difference was not statistically significant. no fetal anomalies were seen in the two groups. conclusion: taking metformin not only has therapeutic effects on infertility but also its con-sumption during the first trimester of pregnancy may have beneficial effects on the course of pregnancy without an increased risk of teratogenicity. proving the beneficial effects of metformin during pregnancy and its harmlessness requires studies with larger sample sizes of pcos patients with precise recording of data while considering its use before and during pregnancy and accurate recording of pregnancy outcomes.< pan>

Keywords: Infertility, Metformin, Pregnancy, Spontaneous abortion, Gestational diabetes, Fetal anomalies, Polycystic ovary syndrome

To cite this article:


  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggo-ner W, Boots LR, Azziz R. Prevalence of the polycys-tic ovary syndrome in unselected black and white women of the southeastern United States: A prospec-tive study. J Clin Endocrinol Metab. 1998;83(9)3078-82.   [PubMed]
  2. Glueck CJ, Philips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75(1):46-52.   [PubMed]
  3. Jakubowicz DJ, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, et al. Insu-lin reduction with metformin increases luteal phase serum glycodelin and insuline-like growth factor-bind-ing protein 1 concentratins. J Clin Endocrinol Metab. 2001;(86):1026-33.   [PubMed]
  4. Elder AT, Hague WM, Davoren PM, Oliver J, Rowan J, Jones P, Yate P, Jones GC. Contraindication to the use of metformin. BMJ. 2003:326(7379):8-9.   [Abstract]
  5. Mathew HM. Use of metformin in endocrinopathy other than diabetes. BMJ. 2003;326:10-1.
  6. Jakubowicz DJ, Luorono MJ, Jakubowicz S, Robert KA, Nestler JE. Effects of metformin on early pregnan-cy loss in the poly cystic ovary syndrome. J Clin Endo-crinol Metab. 2002;87(2):524-9.   [PubMed]
  7. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod. 2004;19 (6):1323-30.   [PubMed]
  8. Glueck CJ, Sieve L, Zhu B, Wang P. Metformin admin-istration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. Clin Endocrinol. 2005;63(6):631-5.   [PubMed]
  9. Thatcher SS, Jackson EM. Pregnancy outcome in infer-tile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril. 2006;85(4):1002-9.   [PubMed]
  10. Koren G, Gilbert C, Valois M. Metformin use during the first trimester of pregnancy. Is it safe?. Can Fam Physician. 2006;52(2):171-2.   [PubMed]
  11. Hughes RC, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23(3):323-6.   [PubMed]
  12. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67-72.   [PubMed]
  13. Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public Health. 2000;90 (9):1452-4.   [PubMed]
  14. Khattab S, Mohsen IA, Foutouh IA, Ramadan A, Moaz M, AI-Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22(12):680-4.   [PubMed]
  15. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion follow-ing assisted reproductive technology treatment. Hum Reprod. 2001;16(12):2606-9.   [PubMed]
  16. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycys-tic ovarian syndrome. Hum Reprod. 2001;16(2):226-9.   [PubMed]
  17. مطالعه برآورد بار بیماریها، دفتر گسترش و توسعه وزارت بهداشت، درمان، آموزش پزشکی، معاونت سلامت، 1384.
  18. The Rotterdam ESHRE/Asrm-Sponsored PCOS Con-sensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1): 41-7. Review.   [PubMed]
  19. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P.Metformin, pre-eclampsia and pregnancy outcomes in women with polycystic ovary syndrome .Diabet Med .2004;21(8):829-36.   [PubMed]
  20. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy through pregnancy redu-ces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77 (3):520-5.   [PubMed]
  21. Brock B, Smidt K, Ovesen P, Schmitz O, Rungby J. Is metformin therapy for polycystic ovary syndrome safe during Pregnancy?. Basic Clin Pharmacol Toxicol. 2005;96(6):410-2.   [PubMed]


Home | About Us | Current Issue | Past Issues | Submit a Manuscript | Instructions for Authors | Subscribe | Search | Contact Us

"Journal of Reproduction & Infertility" is owned, published, and managed by Avicenna Research Institute .
Creative Commons License

This work is licensed under a Creative Commons Attribution –NonCommercial 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Journal of Reproductoin and Infertility (JRI) is a member of COMMITTEE ON PUBLICATION ETHICS . Verify here .

©2024 - eISSN : 2251-676X, ISSN : 2228-5482, For any comments and questions please contact us.